Family Aids Coalition

09/17/2017

http://www.aidsmap.com/Lipids-improved-by-switching-from-ritonavir-to-cobicistat-as-a-booster-for-darunavir/page/3169509/

Switching from ritonavir to cobicistat is associated with significant improvements in cholesterol and triglyceride levels for people with dyslipidaemia, investigators from Spain report in HIV Medicine. Ritonavir was replaced with cobicistat to boost the protease inhibitor darunavir. Six months after...

09/17/2017

http://www.aidsmap.com/Case-reports-of-severe-dolutegravir-related-depression/page/3169506/

Severe depression can be a side-effect of treatment with the anti-HIV drug dolutegravir. In HIV Medicine, clinicians from the Netherlands report two cases of rapid onset of serious depression after initiation of therapy with the drug. The authors are persuaded that dolutegravir was the cause. In nei...

09/17/2017

http://www.aidsmap.com/The-availability-of-direct-acting-antivirals-is-reducing-disparities-in-the-uptake-of-hepatitis-C-treatment/page/3167426/

An analysis from British Columbia, Canada shows that older people, individuals with HIV co-infection, people with cirrhosis and – to some extent – injecting drugs users have been significantly more likely to receive directly acting antiviral treatments, compared to the older interferon-based treatme...

09/17/2017

http://www.aidsmap.com/One-in-seven-people-offered-PrEP-in-African-study-start-it-immediately/page/3167081/

One in seven (14%) of people offered PrEP in a large community study of enhanced HIV testing and treatment in Kenya and Uganda started PrEP the day they were offered it, and 18% within a month, the IAS 2017 conference in Paris heard last month. Of those who were assessed by an HIV risk score al...

09/17/2017

09/17/2017

A friend sent in this video of our Annual Holiday Food Drive.